Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2025 of 2529 entries
View as:

Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients

Phase: N/A Priority: Normal
NCT ID: NCT05963282 Org: User:
Start: 11/29/21 End: 07/19/22 Due: 07/19/23

Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00046748 Org: User:
Start: 12/31/01 End: 04/30/04 Due: 04/30/05

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03131453 Org: User:
Start: 08/03/17 End: 03/26/20 Due: 03/26/21

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

Phase: N/A Priority: Normal
NCT ID: NCT06881823 Org: User:
Start: 06/27/25 End: 06/01/33 Due: 06/01/34

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Phase: N/A Priority: Normal
NCT ID: NCT03591510 Org: User:
Start: 03/13/19 End: 10/01/29 Due: 10/01/30

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00866697 Org: User:
Start: 05/26/09 End: 08/24/17 Due: 08/24/18

Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Phase: N/A Priority: Normal
NCT ID: NCT04765657 Org: User:
Start: 03/01/21 End: 12/28/26 Due: 12/28/27

Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05874817 Org: User:
Start: 05/01/21 End: 05/20/22 Due: 05/20/23

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Phase: N/A Priority: Normal
NCT ID: NCT01787552 Org: User:
Start: 05/08/13 End: 04/10/18 Due: 04/10/19

To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol

Phase: N/A Priority: Normal
NCT ID: NCT01272362 Org: User:
Start: 04/30/10 End: 05/31/12 Due: 05/31/13

Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.

Phase: N/A Priority: Normal
NCT ID: NCT02017860 Org: User:
Start: 01/16/14 End: 04/25/19 Due: 04/25/20

Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

Phase: N/A Priority: Normal
NCT ID: NCT04712721 Org: User:
Start: 10/14/21 End: 07/01/24 Due: 07/01/25

Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)

Phase: N/A Priority: Normal
NCT ID: NCT01846273 Org: User:
Start: 08/07/13 End: 03/02/17 Due: 03/02/18

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01160211 Org: User:
Start: 05/05/11 End: 06/06/22 Due: 06/06/23

First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05275855 Org: User:
Start: 04/29/22 End: 12/18/24 Due: 12/18/25

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03081234 Org: User:
Start: 03/31/18 End: 11/17/25 Due: 11/17/26

Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.

Phase: N/A Priority: Normal
NCT ID: NCT01649466 Org: User:
Start: 08/31/12 End: 10/31/13 Due: 10/31/14

Observational Registry Study of Renal Transplant Patients

Phase: N/A Priority: Normal
NCT ID: NCT01284257 Org: User:
Start: 06/30/07 End: 05/31/10 Due: 05/31/11

Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)

Phase: N/A Priority: Normal
NCT ID: NCT00411580 Org: User:
Start: 06/30/05 End: 12/31/08 Due: 12/31/09

Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity

Phase: N/A Priority: Normal
NCT ID: NCT05304949 Org: User:
Start: 06/22/22 End: 01/11/25 Due: 01/11/26

Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis

Phase: N/A Priority: Normal
NCT ID: NCT03372083 Org: User:
Start: 01/16/18 End: 12/05/19 Due: 12/05/20

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03668613 Org: User:
Start: 08/29/18 End: 09/12/23 Due: 09/12/24

Efficacy, Safety and Tolerability of KLU156 in Adults and Children ≥ 5 kg Body Weight With Uncomplicated P. Falciparum Malaria

Phase: N/A Priority: Normal
NCT ID: NCT05842954 Org: User:
Start: 03/07/24 End: 08/11/27 Due: 08/11/28

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT00894868 Org: User:
Start: 05/31/09 End: 08/31/12 Due: 08/31/13

Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye

Phase: N/A Priority: Normal
NCT ID: NCT01986907 Org: User:
Start: 03/04/14 End: 06/15/16 Due: 06/15/17